10.11.21
A hyaluronic acid (HA) matrix ingredient formulated for joint health, marketed by Bioiberica as Mobilee, was linked in a recent clinical study to multiple markers of joint health in a study on 55 dogs, including the production of HA in the joints, reductions in biomarkers of osteoarthritis, and more.
The randomized, double-blind clinical study set out to evaluate the effects of orally administered Mobilee on 55 dogs, with a supplementation period beginning soon after Cranial Cruciate Ligament (CCL) surgery in the study population. During the investigation, one group of dogs was given a control, where the second group received Mobilee for 10 weeks post-surgery. The authors chose synovitis (inflammation of the synovial fluid in joints) secondary to CCL surgery in canines as it is a widely-studied and characterized model for osteoarthritis research, and is the leading cause of lameness in dogs.
Synovial fluid samples were obtained before the surgery and then at 10 weeks postoperatively to measure key biomarkers of osteoarthritis, including concentrations of HA, haptoglobin, nitric oxide, and paraoxonase-1 (PON-1).
At the end of the 10-week postoperative period, there was a significant increase in HA concentration in the synovial fluid of dogs who received Mobilee supplements, as well as a significant decrease in PON-1, a marker of osteoarthritis, compared to baseline and to the placebo group. These positive changes in biomarkers, as a result of postoperative administration of Mobilee, may represent a significant breakthrough in the role HA can have in managing joint conditions, the authors concluded.
“The use of HA has been widely demonstrated as a joint lubricant, analgesic, and inhibitor of the production of matrix metalloproteases and other cytokine-induced inflammatory mediators,” the authors of the study concluded. “The results demonstrated that postoperative oral administration of [Mobilee] in canine patients with osteoarthritis secondary to CCL injury leads to improvements in OA biomarkers measured in synovial fluid...”
“Despite this research involving dogs specifically, the results are an important indicator for Mobilee’s effect in humans too,” Jaume Reguant, healthcare director of Bioiberica, said. “The findings further contribute to a robust body of evidence which indicates Mobilee’s ability to increase endogenous HA levels and its role in supporting joint and muscle health. Science is at the heart of everything we do at Bioiberica – it’s the means through which we continue to deliver cutting-edge ingredients to support our customers’ product developments.”
The randomized, double-blind clinical study set out to evaluate the effects of orally administered Mobilee on 55 dogs, with a supplementation period beginning soon after Cranial Cruciate Ligament (CCL) surgery in the study population. During the investigation, one group of dogs was given a control, where the second group received Mobilee for 10 weeks post-surgery. The authors chose synovitis (inflammation of the synovial fluid in joints) secondary to CCL surgery in canines as it is a widely-studied and characterized model for osteoarthritis research, and is the leading cause of lameness in dogs.
Synovial fluid samples were obtained before the surgery and then at 10 weeks postoperatively to measure key biomarkers of osteoarthritis, including concentrations of HA, haptoglobin, nitric oxide, and paraoxonase-1 (PON-1).
At the end of the 10-week postoperative period, there was a significant increase in HA concentration in the synovial fluid of dogs who received Mobilee supplements, as well as a significant decrease in PON-1, a marker of osteoarthritis, compared to baseline and to the placebo group. These positive changes in biomarkers, as a result of postoperative administration of Mobilee, may represent a significant breakthrough in the role HA can have in managing joint conditions, the authors concluded.
“The use of HA has been widely demonstrated as a joint lubricant, analgesic, and inhibitor of the production of matrix metalloproteases and other cytokine-induced inflammatory mediators,” the authors of the study concluded. “The results demonstrated that postoperative oral administration of [Mobilee] in canine patients with osteoarthritis secondary to CCL injury leads to improvements in OA biomarkers measured in synovial fluid...”
“Despite this research involving dogs specifically, the results are an important indicator for Mobilee’s effect in humans too,” Jaume Reguant, healthcare director of Bioiberica, said. “The findings further contribute to a robust body of evidence which indicates Mobilee’s ability to increase endogenous HA levels and its role in supporting joint and muscle health. Science is at the heart of everything we do at Bioiberica – it’s the means through which we continue to deliver cutting-edge ingredients to support our customers’ product developments.”
